TLR7 signal activation using MYD88 as an adaptor protein is reported to trigger anti-tumor immunity by stimulating secretion of inflammatory cytokines such as IL-6 and IL-12 in a NF-kB dependent manner, which are downstream transcription factors, leading to the secretion of type-1 interferons via IRF7 (8, 9). This evidence concerns the gene TLR7 and neoplasm.